At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Fulvestrantdrug
Likely dose
Fulvestrant 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fulvestrant in Hormone-refractory Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Fulvestrant for Prostatic Neoplasms and Prostate Cancer. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have a rising serum prostate specific antigen (PSA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasms, Prostate Cancer
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedMay 2007
Primary CompletionSep 2009
Study CompletionDec 2009
TodayJul 2026
First PostedMay 22, 2007
Enrollment StartSep 1, 2006
Primary CompletionSep 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.1 years ago
Interventions
Fulvestrantdrug
Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly